Lineage Cell Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Lineage Cell Therapeutics reported Q2 2026 net income of $1.5M (vs. $30.5M loss in Q2 2025), driven primarily by a $9.4M favorable warrant liability remeasurement and absence of prior-year $14.8M intangible asset impairment. Cash and marketable securities stood at $50.8M as of June 30, 2026, expected to fund operations into Q3 2028. Operating cash burn was $15.3M for the first six months of 2026. Key pipeline developments: OpRegen Phase 1/2a showed sustained 36-month efficacy data; new COR1 corneal endothelial cell program advanced to in-vivo testing; OPC1 spinal cord injury trial opened second clinical site; ReSonance auditory neuron program established 3-year research collaboration with William Demant Invest A/S.
Why this rating
Q2 net income artificial (warrant fair-value swing); underlying burn ~$15.3M/6mo (~$30M/year) is material relative to $161.5M market cap but company has ~24mo runway. Clinical progress routine; no major partnership/financing changes. Modest positive data; balanced development risk.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.